Abstract

Considering the role of retinoids in regulation of more than 500 genes involved in cell cycle and growth arrest, a detailed understanding of the mechanism and its regulation is useful for therapy. The extract of the medicinal plant Neem (Azadirachta indica) is used against several ailments especially for anti-inflammatory, anti-itching, spermicidal, anticancer, and insecticidal activities. In this report we prove the detailed mechanism on the regulation of retinoic acid-mediated cell signaling by azadirachtin, active components of neem extract. Azadirachtin repressed all trans-retinoic acid (ATRA)-mediated nuclear transcription factor κB (NF-κB) activation, not the DNA binding but the NF-κB-dependent gene expression. It did not inhibit IκBα degradation, IκBα kinase activity, or p65 phosphorylation and its nuclear translocation but inhibited NF-κB-dependent reporter gene expression. Azadirachtin inhibited TRAF6-mediated, but not TRAF2-mediated NF-κB activation. It inhibited ATRA-induced Sp1 and CREB (cAMP-response element-binding protein) DNA binding. Azadirachtin inhibited ATRA binding with retinoid receptors, which is supported by biochemical and in silico evidences. Azadirachtin showed strong interaction with retinoid receptors. It suppressed ATRA-mediated removal of retinoid receptors, bound with DNA by inhibiting ATRA binding to its receptors. Overall, our data suggest that azadirachtin interacts with retinoic acid receptors and suppresses ATRA binding, inhibits falling off the receptors, and activates transcription factors like CREB, Sp1, NF-κB, etc. Thus, azadirachtin exerts anti-inflammatory and anti-metastatic responses by a novel pathway that would be beneficial for further anti-inflammatory and anti-cancer therapies.

Highlights

  • Vitamin A and its physiological metabolites, retinoic acid and other retinoids, act as morphogens that control embryonic development [1, 2]

  • In this study we examined the effect of azadirachtin on all trans-retinoic acid (ATRA)-induced biological responses in lung carcinoma cells

  • In this report we demonstrate a novel action of azadirachtin against ATRA-mediated biological responses

Read more

Summary

EXPERIMENTAL PROCEDURES

RPMI 1640 medium, antibiotics-antimycotic, and fetal bovine serum were obtained from Invitrogen. Azadirachtin, leupeptin, methyl umbelliferyl phosphate, ATRA, DAPI, PMSF, pepstatin, and anti-tubulin antibody were obtained from Sigma. Recombinant human TNF was obtained from Peprotech Inc. Antibodies against I␬B␣, p65, p50, cyclin D1, c-Rel, RAR␣, RXR, CRM1, ␤-adaptin, and doublestranded NF-␬B, Sp1, and CREB gel shift oligonucleotides were obtained from Santa Cruz Biotechnology, Inc. The histone H3 and Alexa Fluor-conjugated antirabbit IgGs were obtained from Millipore (Billerica, MA). The SuperFect transfection reagent was purchased from Qiagen (Hilden, Germany). Plasmid constructs for NF-␬B-SEAP, TRAF2, and TRAF6 were provided by Prof. Aggarwal (MD Anderson Cancer Center, Houston, TX). GST-I␬B and GST-p65 were cloned, expressed, and purified in the laboratory and used as substrates for kinases

Cell Lines
In Vitro Assay for IKK and PKA
Western Blot
Study of Molecular Docking
RESULTS
Free energy of bindingc
Lowest energyc
DISCUSSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.